Summary of opinion: Noxafil, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Noxafil, 29/01/2026 Positive
Summary of opinion: Kerendia, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Kerendia, 29/01/2026 Positive
Summary of opinion: Eurneffy, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Eurneffy, 29/01/2026 Positive
Summary of opinion: Iclusig, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Iclusig, 29/01/2026 Positive
Summary of opinion: Zynyz, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Zynyz, 29/01/2026 Positive
Summary of opinion: Efmody, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Efmody, 29/01/2026 Positive
Summary of opinion: Akeega, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Akeega, 29/01/2026 Positive
EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA
Summary of opinion: Imfinzi, 29/01/2026 Positive
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Summary of opinion: Imfinzi, 29/01/2026 Positive
Human medicines European public assessment report (EPAR): Rezurock, Belumosudil, Status: Opinion
Submitted by Anonymous (not verified) on 30 January 2026 - 11:00
Human medicines European public assessment report (EPAR): Rezurock, Belumosudil, Status: Opinion